Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lansoprazole
Drug ID BADD_D01245
Description Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]
Indications and Usage Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]
Marketing Status approved; investigational
ATC Code A02BC03
DrugBank ID DB00448
KEGG ID D00355
MeSH ID D064747
PubChem ID 3883
TTD Drug ID D06YYD
NDC Product Code 11532-1441; 49711-0110; 52932-0730; 53104-7526; 55111-044; 16714-185; 0113-0117; 49035-373; 50090-6154; 55111-739; 56062-283; 60687-123; 61919-655; 63629-2340; 0378-8030; 68382-543; 68382-544; 69842-755; 0536-1368; 55111-399; 65628-080; 0093-3008; 0113-0116; 41163-150; 41250-391; 62175-515; 63739-555; 63868-429; 68788-6390; 70000-0612; 71335-0043; 71335-9693; 80425-0148; 43598-109; 66332-1443; 16571-698; 36800-295; 43598-560; 45802-245; 50090-5180; 51079-121; 55111-398; 55154-0253; 55910-307; 0363-0037; 0363-1212; 64764-541; 65862-896; 67877-274; 68071-2734; 71335-1820; 71335-2078; 72189-062; 55154-4848; 61919-890; 63981-117; 0378-6981; 65841-770; 68391-117; 71335-0917; 72288-343; 82009-039; 51927-0064; 65372-1136; 16571-697; 21130-046; 30142-983; 46122-698; 51316-006; 55289-704; 68001-112; 68382-771; 70771-1132; 71335-0058; 71335-9680; 72189-279; 81522-001; 51552-1239; 51927-0262; 65977-0013; 71052-242; 75945-567; 11673-117; 11822-0016; 11822-0019; 16714-186; 0093-3009; 0093-7350; 31722-570; 0113-6117; 41250-117; 43598-161; 43598-561; 46122-107; 60760-544; 64764-046; 68071-2274; 68071-5119; 70000-0069; 71335-1521; 71335-9694; 80425-0174; 0378-3995; 38779-2289; 42765-023; 63850-3309; 64374-007; 65015-658; 66332-1442; 0113-6002; 0113-7116; 41520-816; 49035-411; 50090-6079; 0363-0739; 0378-8015; 65862-895; 68001-111; 68196-045; 71335-0575; 71335-1425; 16571-742; 0093-7351; 30142-192; 51407-324; 0363-1419; 64764-543; 65841-769; 68016-758; 68382-772; 69256-401; 69842-270; 70700-262; 70756-806; 70756-807; 70771-1133; 72288-301; 83324-001; 63415-0060; 11673-280; 11822-3374; 31722-571; 0113-7003; 41163-117; 45865-879; 49348-301; 56062-117; 60687-111; 62011-0168; 63187-152; 63629-4851; 63981-582; 69842-507; 79903-068; 11532-1440; 21130-564; 27241-019; 27241-020; 30142-288; 45802-878; 63187-510; 0363-4069; 63629-2341; 63629-2342; 64764-544; 0378-6982; 67877-275; 68788-7742; 70000-0508; 70677-0124; 0536-1324; 70700-263; 71335-9695; 72288-829; 72476-020; 0904-6662; 51927-0256; 52562-021; 59349-0015; 11822-0117; 21130-181; 30142-117; 0113-1114; 36800-117; 36800-392; 37808-755; 43598-883; 49035-739; 55910-117
UNII 0K5C5T2QPG
Synonyms Lansoprazole | Lansoprazol | 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole | Lansoprazoles | Ogastro | AG 1749 | AG-1749 | AG1749 | Agopton | Bamalite | Lansol | Lansoprazole Sodium | Sodium, Lansoprazole | Lanzor | Monolitum | Opiren | Prevacid | Pro Ulco | Promeco | Takepron | Ulpax | Zoton | Ogast | Prezal
Chemical Information
Molecular Formula C16H14F3N3O2S
CAS Registry Number 103577-45-3
SMILES CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertensive nephropathy20.01.08.004; 24.08.05.0030.000249%-
Cutaneous lupus erythematosus10.04.03.007; 15.06.02.007; 23.03.02.0080.000249%-
Colitis microscopic07.08.01.0110.005539%-
Rectal tenesmus07.03.03.001; 15.05.03.011---
Cognitive disorder17.03.03.003; 19.21.02.001--
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.001492%-
Nuchal rigidity15.05.04.005; 17.05.02.006---
Vasodilation procedure25.03.01.001---
Disturbance in sexual arousal19.08.04.003---
Protein-losing gastroenteropathy07.11.01.013; 14.03.02.0150.000298%-
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Cardiac disorder02.11.01.003---
Feeding disorder14.03.02.003; 19.09.01.0030.000418%-
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.0040.000149%-
Oesophageal disorder07.11.02.001---
White blood cell disorder01.02.05.002---
Abnormal behaviour19.01.01.0010.000368%-
Decreased appetite08.01.09.028; 14.03.01.0050.001581%
Erectile dysfunction19.08.04.001; 21.03.01.007--
Renal injury12.01.05.001; 20.01.03.0150.002088%-
Ill-defined disorder08.01.03.049---
Polyp08.01.06.010; 16.02.02.005---
Red blood cell abnormality01.07.02.006---
Sensation of foreign body08.01.09.0020.000517%-
Urinary tract obstruction20.08.01.0040.000099%
Vocal cord disorder22.04.01.0030.000099%-
The 18th Page    First    Pre   18 19 20 21    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene